Advanced Biomed Inc. has sold its Hong Kong subsidiary to Wei Ha Hui for USD 23,000 to streamline operations and centralize clinical trials in Taiwan.

Information on the Target

Advanced Biomed Inc. has announced the sale of its wholly-owned Hong Kong subsidiary, Advanced Biomed (HK) Limited, to an unrelated third party, Wei Ha Hui, for a total purchase price of USD 23,000. This agreement, finalized on December 23, 2025, involved the transfer of 100% of the outstanding shares of the subsidiary, as well as all associated intellectual property, including that belonging to Shanghai Sglcell Biotech Co., Ltd., another wholly owned subsidiary of Advanced Biomed (HK) Limited.

The divestiture of the Hong Kong subsidiary aligns with Advanced Biomed's strategic aim to streamline operations and address evolving regulatory challenges in China. Moving forward, the company's clinical trials will be centralized through its Taiwan subsidiary, allowing for enhanced focus on the development and commercialization of its biomedical products.

Industry Overview in Hong Kong

The biotechnology industry in Hong Kong has shown significant growth in recent years, driven by advancements in research and development, as well as increased investment from local and